TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Stanford University
Eilean Therapeutics
University of Alabama at Birmingham
City of Hope Medical Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Chicago
City of Hope Medical Center
Mayo Clinic
Hangzhou GluBio Pharmaceutical Co., Ltd.
American Regent, Inc.
University of Virginia
AbbVie
Epigenetix, Inc.
Astex Pharmaceuticals, Inc.
Fox Chase Cancer Center
Newave Pharmaceutical Inc
City of Hope Medical Center
OHSU Knight Cancer Institute
Dartmouth-Hitchcock Medical Center
Lynk Pharmaceuticals Co., Ltd
Prelude Therapeutics
Taiga Biotechnologies, Inc.
Medigene AG
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
Tarix Pharmaceuticals
Case Comprehensive Cancer Center
Daiichi Sankyo
Mayo Clinic
University of Pittsburgh
Stanford University
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
California Cancer Consortium
Massachusetts General Hospital
University of Louisville
Washington University School of Medicine
Yale University
Prescient Therapeutics, Ltd.
Alliance for Clinical Trials in Oncology
JW Pharmaceutical
City of Hope Medical Center
National Cancer Institute (NCI)
Children's Oncology Group
Indiana University
Indiana University
Duke University